Research location
Schwerte
North Rhine-Westphalia, Germany
Advertisement
Research activity in Schwerte
North Rhine-Westphalia, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Schwerte
9 linked trials · page 1 of 1Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCNCT07242352 · 2026-04-29 · 1 site observation
RECRUITING
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 1 site observation
RECRUITING
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)NCT06081244 · 2024-10-10 · 1 site observation
RECRUITING
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerNCT05704829 · 2024-02-05 · 1 site observation
RECRUITING
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNCT07178730 · 2026-08-30 · 1 site observation
NOT_YET_RECRUITING
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBCNCT04565054 · 2020-09-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCNCT04055493 · 2019-07-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D MammographyNCT03377036 · 2018-07-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Therapy Management With Nab-Paclitaxel in Daily RoutineNCT02642406 · 2015-12-01 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.